Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
SAGE Sage Therapeutics	$6.70 +1.5%	$6.97	$4.62 ▼ $13.47	$419.56M	0.18	1.16 million shs	647,192 shs
SIGA SIGA Technologies	$6.36 -1.2%	$5.98	$4.95 ▼ $12.83	$454.37M	0.93	732,446 shs	502,961 shs
TECX Tectonic Therapeutic	$21.89 -2.5%	$20.58	$13.70 ▼ $61.07	$408.75M	3.25	173,408 shs	155,942 shs
UNCY Unicycive Therapeutics	$0.68 +6.8%	$0.62	$0.20 ▼ $1.10	$82.20M	2.01	1.96 million shs	4.32 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
SAGE Sage Therapeutics	0.00%	-2.19%	+1.36%	-13.21%	-38.25%
SIGA SIGA Technologies	0.00%	+5.47%	+7.43%	+13.98%	-19.29%
TECX Tectonic Therapeutic	0.00%	-5.07%	+5.80%	-14.59%	+2,188,999,900.00%
UNCY Unicycive Therapeutics	0.00%	-9.68%	+23.76%	+16.48%	+3.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
SAGE Sage Therapeutics	3.5778 of 5 stars	3.0	1.0	4.0	1.4	1.7	1.3
SIGA SIGA Technologies	2.4352 of 5 stars	0.0	3.0	0.0	2.7	0.8	3.1
TECX Tectonic Therapeutic	3.2834 of 5 stars	3.6	2.0	0.0	2.1	5.0	0.6
UNCY Unicycive Therapeutics	3.5592 of 5 stars	3.8	5.0	0.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
SAGE Sage Therapeutics	2.06	Hold	$8.87	32.34% Upside
SIGA SIGA Technologies	0.00	N/A	N/A	N/A
TECX Tectonic Therapeutic	3.25	Buy	$82.33	276.12% Upside
UNCY Unicycive Therapeutics	3.50	Strong Buy	$6.00	780.54% Upside

Current Analyst Ratings Breakdown

Latest UNCY, SIGA, TECX, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	TECX Tectonic Therapeutic	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$9.00
5/15/2025	TECX Tectonic Therapeutic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$51.00 ➝ $85.00
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/21/2025	TECX Tectonic Therapeutic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
4/21/2025	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
4/11/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/1/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.50
3/21/2025	TECX Tectonic Therapeutic	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$112.00 ➝ $101.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
SAGE Sage Therapeutics	$47.40M	8.85	N/A	N/A	$7.56 per share	0.89
SIGA SIGA Technologies	$120.33M	3.78	$1.00 per share	6.34	$2.77 per share	2.30
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$2.13 per share	N/A
UNCY Unicycive Therapeutics	$680K	120.88	N/A	N/A	($0.11) per share	-6.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-971.50%	-68.18%	-60.84%	7/30/2025 (Estimated)
SIGA SIGA Technologies	$68.07M	$0.67	5.30	5.09	N/A	49.33%	49.06%	38.72%	7/30/2025 (Estimated)
TECX Tectonic Therapeutic	$12.16M	-$7.31	N/A	N/A	N/A	N/A	-35.53%	-31.97%	8/13/2025 (Estimated)
UNCY Unicycive Therapeutics	-$30.54M	-$0.51	N/A	N/A	N/A	N/A	N/A	-29.88%	N/A

Latest UNCY, SIGA, TECX, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	UNCY Unicycive Therapeutics	-$0.14	-$0.05	+$0.09	-$0.05	N/A	N/A
5/8/2025	Q1 2025	SIGA SIGA Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million
3/27/2025	Q4 2024	UNCY Unicycive Therapeutics	-$0.13	-$0.26	-$0.13	-$0.26	N/A	N/A
3/20/2025	Q4 2024	TECX Tectonic Therapeutic	-$1.39	-$0.84	+$0.55	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA SIGA Technologies	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest UNCY, SIGA, TECX, and SAGE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/8/2025	SIGA SIGA Technologies	special	$0.60		4/29/2025	4/29/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
SAGE Sage Therapeutics	N/A	7.42	7.42
SIGA SIGA Technologies	N/A	8.10	5.32
TECX Tectonic Therapeutic	N/A	9.39	9.39
UNCY Unicycive Therapeutics	N/A	3.61	3.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
SAGE Sage Therapeutics	99.22%
SIGA SIGA Technologies	55.40%
TECX Tectonic Therapeutic	62.63%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
SAGE Sage Therapeutics	5.50%
SIGA SIGA Technologies	1.95%
TECX Tectonic Therapeutic	38.00%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
SAGE Sage Therapeutics	690	62.62 million	58.10 million	Optionable
SIGA SIGA Technologies	40	71.44 million	70.31 million	Optionable
TECX Tectonic Therapeutic	120	18.67 million	13.40 million	N/A
UNCY Unicycive Therapeutics	9	120.63 million	78.78 million	Not Optionable

UNCY, SIGA, TECX, and SAGE Headlines

Recent News About These Companies

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 46.4% in May

June 15 at 10:09 AM | marketbeat.com

Brookline Capital Management Weighs in on UNCY Q3 Earnings

June 14 at 1:45 AM | americanbankingnews.com

UNCY Q3 EPS Forecast Raised by Brookline Capital Management

June 12 at 7:52 AM | marketbeat.com

Kaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations

June 11, 2025 | theglobeandmail.com

Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m

June 11, 2025 | finance.yahoo.com

Unicycive Shares Slide as FDA Flags Issues Related to Kidney Drug Application

June 10, 2025 | marketwatch.com

Unicycive Therapeutics stock tumbles after FDA flags manufacturing issues

June 10, 2025 | investing.com

Unicycive Therapeutics Addresses FDA Deficiencies in OLC NDA Process, Awaiting Final Decision by June 2025

June 10, 2025 | quiverquant.com

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

June 10, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Drop in Short Interest

June 3, 2025 | marketbeat.com

What is HC Wainwright's Estimate for UNCY Q2 Earnings?

May 30, 2025 | marketbeat.com

Q4 Earnings Estimate for UNCY Issued By HC Wainwright

May 29, 2025 | marketbeat.com

Unicycive Therapeutics' (UNCY) "Buy" Rating Reiterated at HC Wainwright

May 28, 2025 | marketbeat.com

Unicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor Conferences

May 22, 2025 | quiverquant.com

Unicycive Therapeutics to Present at Upcoming Investor Conferences

May 22, 2025 | globenewswire.com

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

May 21, 2025 | globenewswire.com

Q2 Earnings Forecast for UNCY Issued By Noble Financial

May 20, 2025 | marketbeat.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Acquired by Octagon Capital Advisors LP

May 15, 2025 | marketbeat.com

Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | finanznachrichten.de

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | globenewswire.com

Analysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before Long

May 7, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY, SIGA, TECX, and SAGE Company Descriptions

Sage Therapeutics NASDAQ:SAGE

$6.70 +0.10 (+1.52%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.72 +0.02 (+0.30%)

As of 06/13/2025 07:14 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SIGA Technologies NASDAQ:SIGA

$6.36 -0.08 (-1.24%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.36 0.00 (-0.08%)

As of 06/13/2025 04:23 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Tectonic Therapeutic NASDAQ:TECX

$21.89 -0.55 (-2.45%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$21.89 0.00 (0.00%)

As of 06/13/2025 04:44 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Unicycive Therapeutics NASDAQ:UNCY

$0.68 +0.04 (+6.82%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.68 +0.00 (+0.23%)

As of 06/13/2025 07:59 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time